UTHealth joins NIH trial to test antibodies and other experimental outpatient treatments for mild COVID-19 pneumonia

October 1, 2020

The first treatment being tested is LY-CoV555, an investigational monoclonal (laboratory-manufactured) antibody developed from the blood sample of a recovered COVID-19 patient. (Photo by: Getty Images)

A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

UTHealth is launching the Houston site of the nationwide ACTIV-2 trial, a public-private partnership led by the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. Operation Warp Speed, a multi-agency effort led by the U.S. government to develop, manufacture, and distribute COVID-19 vaccines, therapies, and diagnostics, also coordinates the study.

Read the full story…

September 15, 2020

Share content